Aclarion says cash runway extends into 2028, ends equity facilities

Aclarion Inc. (NASDAQ: ACON, ACONW) announced it has sufficient cash to operate into 2028 and terminated its at-the-market equity offering program while allowing its equity line of credit to expire December 31, 2025.

The healthcare technology company released its 2026 shareholder letter outlining financial and operational priorities as it advances toward an initial internal readout of its 300-patient CLARITY trial expected at the end of the third quarter, with public disclosure of early interim results anticipated in the fourth quarter of 2026.

"Aclarion enters 2026 with a strengthened balance sheet, a scalable software-native business model, and a clear path to an initial readout on our CLARITY trial," said Jeff Thramann, Executive Chairman of Aclarion. "With cash runway into 2028 and a clean capital structure, we are fully funded to deliver this important clinical milestone."

The company currently has 2,882,371 shares outstanding on a fully diluted basis and stated it will not implement new equity facilities until after reporting initial interim CLARITY results.

Aclarion develops Nociscan, a cloud-based platform that uses magnetic resonance spectroscopy data to help physicians identify potential sources of chronic low back pain by analyzing chemical biomarkers in lumbar discs.

The company plans to execute an investor-awareness strategy in 2026 focused on institutional healthcare investors, physician-led clinical education, and increased visibility in financial and medical media.

Information in this article is based on the company's press release statement.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Active options: TSLA NVDA SPCX MU AAPL AMD INTC AMZN